复方苁蓉益智胶囊治疗肝肾亏虚兼痰瘀阻络型轻中度阿尔茨海默病的效果

doi:10.20047/j.issn1673-7210.2023.08.19

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (660 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Compound Cistanche Yizhi Capsules on mild and moderate Alzheimer’s disease (AD) with deficiency of liver and kidney and phlegm-stasis blocking collaterals. Methods A total of 120 patients with mild and moderate AD with deficiency of liver and kidney and phlegm-stasis blocking collaterals admitted to Lu’an Hospital of Traditional Chinese Medicine from May 2020 to March 2021 were selected, they were divided into control group and study group by random number table method, with 60 cases in each group. The control group was treated with Donepezil Hydrochloride Tablets, while the study group was treated with Compound Cistanche Yizhi Capsules on the basis of the control group, the course of treatment was six months. The clinical efficacy of the two groups after treatment was compared, the cognitive function, self-care ability, estradiol (E2), and hypoxia-inducible factor 1-α (HIF1-α) levels were compared between the two groups before and after treatment, and the adverse reactions during the treatment were recorded in the two groups. Results The clinical efficacy of the study group was better than that of the control group (P＜0.05). After treatment, the mini-mental state scale and Barthel index scores in the two groups were higher than those before treatment, and the study group were higher than those in the control group (P＜0.05); after treatment, E2 in the two groups increased, while HIF1-α decreased, and E2 in the study group was higher than that in the control group, and HIF1-α was lower than that in the control group (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion Compound Cistanche Yizhi Capsules in the treatment of mild and moderate AD with deficiency of liver and kidney and phlegm-stasis blocking collaterals can significantly improve patients’ cognitive function and self-care ability, with definite curative effect and good safety.

Key words： Compound Cistanche Yizhi Capsules Donepezil Hydrochloride Tablets Mild to moderate Alzheimer’s disease Clinical study

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HONG Liang SUN Ping YANG Yanfu FANG Wujie

Cite this article:

HONG Liang SUN Ping YANG Yanfu FANG Wujie. Effect of Compound Cistanche Yizhi Capsules on mild and moderate Alzheimer’s disease with deficiency of liver and kidney and phlegm-stasis blocking collaterals[J]. 中国医药导报, 2023, 20(8): 87-90.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.08.19 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I8/87

[1] 温扬，舒俊，魏文石.衰弱与阿尔茨海默病[J].中华老年心脑血管病杂志，2021，23（4）：447-448.
[2] 贾建平，李妍.中国痴呆的现状和未来[J].中华神经科杂志，2020，53（2）：81-84.
[3] 孟胜喜，霍清萍，王兵，等. 恒清Ⅱ号方联合盐酸多奈哌齐片对阿尔茨海默病病人血清NO、ET-1及肠道菌群的影响[J].中西医结合心脑血管病杂志，2021，19（19）：3283- 3286.
[4] 王旭，姚璇，马素亚，等.复方苁蓉益智胶囊治疗阿尔茨海默病作用机制的网络药理学研究[J].中药新药与临床药理，2021，32（2）：172-181.
[5] 美国精神医学学会，张道龙.精神障碍诊断与统计手册[M].北京：北京大学出版社，2016： 125-126.
[6] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002：93-98.
[7] 中国痴呆与认知障碍诊治指南写作组，中国医师协会神经内科医师分会认知障碍疾病专业委员会. 2018中国痴呆与认知障碍诊治指南（三）：痴呆的认知和功能评估[J].中华医学杂志，2018，98（15）：1125-1129.
[8] 金亚菊，李蕊，魏鲁刚.简易智能精神状态检查量表在老年痴呆患者中的应用研究[J].中国老年保健医学，2009， 7（4）：46-47.
[9] 闵瑜，吴媛媛，燕铁斌.改良Barthel指数（简体中文版）量表评定脑卒中患者日常生活活动能力的效度和信度研究[J].中华物理医学与康复杂志，2008，30（3）：185-188.
[10] 廖伶艺，高长越，高强. 阿尔茨海默病的功能障碍病理机制及康复治疗研究进展[J].中国康复医学杂志，2022， 37（6）：834-839.
[11] 李婉琳，宋勋，叶亮，等. 阿尔茨海默病发病机制及药物治疗方法研究进展[J].中国临床神经科学，2021，29（5）：581-589，596.
[12] 郭佳旗，魏颖鸿，张慧，等.阿尔茨海默病发病机制及基于神经递质治疗的研究进展[J].医学综述，2021，27（19）：3761-3766.
[13] 惠婷，林先萍，刘泓毓.地黄饮子联合盐酸多奈哌齐片治疗轻中度阿尔茨海默病临床研究[J].国际中医中药杂志，2020，42（8）：745-749.
[14] 刘宗鑫，王晋平，谢荣鑫，等.中医药治疗阿尔兹海默病的概况及展望[J].海南医学，2022，33（7）：926-929.
[15] 关徐涛，胡翔燕，詹向红.“五脏致呆”相关理论[J].中国老年学杂志，2019，39（8）：2015-2018.
[16] 张力，李方玲，马丽.六味地黄丸联合西药治疗轻、中度阿尔茨海默病的临床观察[J].世界中医药，2017，12（11）：2659-2661，2665.
[17] 代渊，徐世军.基于肾“主蛰守位”浅析阿尔茨海默病认知障碍发生的机制[J].中国中医基础医学杂志，2022， 28（3）：354-356，386.
[18] 徐美杰，阎涛，赵理乐，等.复方苁蓉益智胶囊联合奥拉西坦治疗轻中度血管性痴呆的临床研究[J].现代药物与临床，2021，36（8）：1594-1598.
[19] 徐丹，陶陶，张继荣，等.HIF-1α对脑缺血再灌注损伤细胞凋亡及凋亡相关基因的研究进展[J].中国神经免疫学和神经病学杂志，2017，24（3）：219-222.
[20] Sahab-Negah S，Hajali V，Moradi HR，et al. The Impact of Est- radiol on Neurogenesis and Cognitive Functions in Alzheimer’s Disease [J]. Cell Mol Neurobiol，2020，40（3）：283-299.
[21] 袁茵，周天，张妍妍，等.何首乌提取物二苯乙烯苷对血管性痴呆模型大鼠内质网应激相关蛋白的影响[J].天津中医药大学学报，2022，41（1）：118-123.
[22] 钟达源，李兰，蒋成婷，等.基于数据挖掘研究现代医家治疗阿尔茨海默病的用药规律[J].中国医药导报，2021， 18（18）：131-135.
[23] 刘心朗，周丽丽，杨占君，等.肉苁蓉总苷对SAMP8小鼠学习记忆能力及突触可塑性的影响[J].中华中医药学刊，2022，40（1）：110-115，18-19.
[24] 李媛媛，刘珂依，宋珂，等.基于网络药理学和分子对接探讨漏芦防治缺血性脑卒中的作用机制[J].中西医结合心脑血管病杂志，2020，18（22）：3735-3744.
[25] 姚凤红，杨福生，苗阳.基于网络药理学探讨复方苁蓉益智胶囊治疗阿尔茨海默病的机制研究[J].内蒙古医科大学学报，2021，43（2）：180-183.
[26] 池鑫宇，杨柯，段云天，等.基于阿尔茨海默病模型小鼠研究不同炮制程度制首乌长期用药对肝肾的影响[J].广西中医药，2022，45（3）：64-68.